Anvisa Certified Pharmaceutical Companies Janssen and Pfizer for An Emergency Use Order
Certifications were made official by Anvisa this Tuesday, 19, and are necessary for emergency use of vaccines against Covid-19 to be requested.
The pharmaceutical companies Janssen and Pfizer received this Tuesday, 19, a seal of good practices in the manufacture of medicines from the National Health Surveillance Agency (Anvisa), one of the prerequisites for requesting the emergency use of immunizers against Covid-19 developed by them in Brazil. In a statement, the regulatory agency said that Pfizer’s certification was made after analyzing the information and that of Janssen, which has three companies involved in the vaccine manufacturing process, had only one pending issue in one of them. In Brazil, the Janssen immunizer is in phase 3 of tests. If the study protocols follow the expected schedule, the results should be released in February and the application for use can be formalized in March.
In Brazil, two vaccines were approved for emergency use on Sunday, 17: that of Coronavac, developed by the Butantan Institute with Chinese technology, and that of Oxford / AstraZeneca, produced in partnership with Fiocruz with British technology. From the moment the request for emergency use of the Janssen and Pfizer vaccines is submitted, the development of the analysis of the documents of each one of them can be followed by the population through a panel developed by Anvisa.